ctDNA in DLBCL: A Blueprint for Better Clinical Trials?

Current clinical characteristics and demographics are not sufficient to capture aggressive disease in clinical trials of newly diagnosed DLBCL. Novel tools, such as measurement of tumor burden via ctDNA, are needed. By : Dr. Matthew Maurer.

Apr 10^th • 7 mins listen